scholarly article | Q13442814 |
P50 | author | Athanasios Dimopoulos | Q26338766 |
H P Kalofonos | Q56432806 | ||
George Fountzilas | Q56432880 | ||
Urania Dafni | Q56605609 | ||
P2093 | author name string | D Pectasides | |
G Aravantinos | |||
H Gogas | |||
H Linardou | |||
E Razis | |||
E Briasoulis | |||
C Christodoulou | |||
P Papakostas | |||
G Zografos | |||
T Economopoulos | |||
A K Koutras | |||
K T Kalogeras | |||
R M Wirtz | |||
Hellenic Cooperative Oncology Group (HeCOG) | |||
E Timotheadou | |||
P2860 | cites work | A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4 | Q24291286 |
The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells | Q24293729 | ||
Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera | Q24595150 | ||
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
The deaf and the dumb: the biology of ErbB-2 and ErbB-3 | Q28185247 | ||
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials | Q29547513 | ||
The Clinical Significance of Epidermal Growth Factor Receptor (EGF-R) in Human Breast Cancer: A Review on 5232 Patients* | Q33188817 | ||
HER2/neu in systemic therapy for women with breast cancer: a systematic review | Q33291068 | ||
Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. | Q33968565 | ||
Reporting recommendations for tumor marker prognostic studies | Q81236405 | ||
Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients | Q81414756 | ||
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer | Q34601123 | ||
HER-2 and topoisomerase II as predictors of response to chemotherapy | Q34747499 | ||
The clinical evaluation of HER-2 status: which test to use? | Q35084775 | ||
Recommendations for HER2 testing in the UK. | Q35395505 | ||
Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis | Q35789663 | ||
Oncogenic growth factor receptors: implications for signal transduction therapy | Q35818569 | ||
C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. | Q36135449 | ||
Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients | Q36643014 | ||
Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer | Q38446760 | ||
Comparative multi-methodological measurement of ERBB2 status in breast cancer | Q40584056 | ||
Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. | Q41093419 | ||
Prognostic value of ERBB family mRNA expression in breast carcinomas | Q43461671 | ||
Epidermal growth factor receptor expression in 780 breast cancer patients: a reappraisal of the prognostic value based on an eight-year median follow-up | Q43695203 | ||
c-erbB-3 protein expression in human breast cancer: comparison with other tumour variables and survival | Q43926200 | ||
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. | Q44362100 | ||
Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer | Q44503047 | ||
Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma | Q44969545 | ||
Adjuvant docetaxel for node-positive breast cancer | Q46522790 | ||
Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients | Q46580491 | ||
Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group | Q46691182 | ||
Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. | Q46813500 | ||
Correlated expression of erbB-3 with hormone receptor expression and favorable clinical outcome in invasive ductal carcinomas of the breast | Q46892411 | ||
Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy | Q46991232 | ||
Epidermal growth factor receptor status in operable invasive breast cancer: is it of any prognostic value? | Q47793792 | ||
Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. | Q53394493 | ||
EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. | Q53810400 | ||
Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization. | Q54628922 | ||
HER2 and Response to Paclitaxel in Node-Positive Breast Cancer | Q57578418 | ||
Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer | Q59616875 | ||
c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer | Q64019053 | ||
Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms | Q71536089 | ||
Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay | Q73269384 | ||
Active signaling by Neu in transgenic mice | Q77430527 | ||
Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer | Q77673978 | ||
Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome | Q79918229 | ||
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system | Q80358653 | ||
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials | Q80408348 | ||
P433 | issue | 11 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 1775-1785 | |
P577 | publication date | 2008-11-04 | |
P1433 | published in | British Journal of Cancer | Q326309 |
P1476 | title | Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study | |
P478 | volume | 99 |
Q36223407 | Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy |
Q92111598 | Application of Multiplex Ligation-Dependent Probe Amplification in Determining the Copy Number Alterations of HER Gene Family Members in Invasive Ductal Breast Carcinoma |
Q54286036 | Association of ErbB1-4 expression in invasive breast cancer with clinicopathological characteristics and prognosis. |
Q27852062 | Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes |
Q54395374 | Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765). |
Q33921374 | ERBB4 promoter polymorphism is associated with poor distant disease-free survival in high-risk early breast cancer |
Q89767940 | ErbB4 3'-UTR Variant (c.*3622A>G) is Associated with ER/PR Negativity and Advanced Breast Cancer |
Q35663809 | Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study |
Q60046313 | Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study |
Q54297439 | Exon 8 amplification of epidermal growth factor receptor (EGFR) in invasive breast carcinomas. |
Q54642874 | Expression of HER-2 and nuclear localization of HER-3 protein in canine mammary tumors: histopathological and immunohistochemical study. |
Q33644491 | Genetically dependent ERBB3 expression modulates antigen presenting cell function and type 1 diabetes risk |
Q35744973 | HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. |
Q39368710 | HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy |
Q31134061 | Inverse regulation of EGFR/HER1 and HER2-4 in normal and malignant human breast tissue |
Q60920835 | Low HIF-1α and low EGFR mRNA Expression Significantly Associate with Poor Survival in Soft Tissue Sarcoma Patients; the Proteins React Differently |
Q33570512 | MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer |
Q27853060 | Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer |
Q37658764 | Potential of ErbB4 antibodies for cancer therapy. |
Q43244620 | Prediction of outcome of patients with metastatic breast cancer: evaluation with prognostic factors and Nottingham prognostic index |
Q42148898 | Prognostic significance of HER3 in patients with malignant solid tumors |
Q90291834 | Quantification of EGFR family in canine mammary ductal carcinomas in situ: implications on the histological graduation |
Q34518357 | STAT-Related Profiles Are Associated with Patient Response to Targeted Treatments in Locally Advanced SCCHN. |
Q36598709 | Sample parameters affecting the clinical relevance of RNA biomarkers in translational breast cancer research |
Q26864668 | Targeting of erbB3 receptor to overcome resistance in cancer treatment |
Q35357793 | The effect of epiregulin on epidermal growth factor receptor expression and proliferation of oral squamous cell carcinoma cell lines |
Q24309041 | WW domain containing E3 ubiquitin protein ligase 1 targets the full-length ErbB4 for ubiquitin-mediated degradation in breast cancer |
Search more.